Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey

  • Serarslan, Alparslan (Department of Radiation Oncology, Faculty of Medicine, Ondokuz Mayis University) ;
  • Gursel, Bilge (Department of Radiation Oncology, Faculty of Medicine, Ondokuz Mayis University) ;
  • Okumus, Nilgun Ozbek (Department of Radiation Oncology, Faculty of Medicine, Ondokuz Mayis University) ;
  • Meydan, Deniz (Department of Radiation Oncology, Faculty of Medicine, Ondokuz Mayis University) ;
  • Sullu, Yurdanur (Department of Pathology, Faculty of Medicine, Ondokuz Mayis University) ;
  • Gonullu, Guzin (Department of Medical Oncology, Faculty of Medicine, Ondokuz Mayis University)
  • Published : 2015.10.06
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Male breast cancer is a rare neoplasm, and its treatments are based on those of female breast cancer. This study aimed to analyze 20 years of male breast cancer clinical characteristics and treatment results from the Middle Black Sea Region of Turkey. Materials and Methods: A retrospective analysis of 16 male breast cancer patients treated in our tertiary hospital between 1994 and 2014 was performed. Epidemiologic data, tumor characteristics, and treatments were recorded and compared with 466 female breast cancer ((premenopausal; n = 230) + (postmenopausal n = 236)) patients. The 5-year disease-free and overall survival rates were calculated. Results: Male breast cancer constituted 0.1% of all malignant neoplasms in both sexes, 0.2% of all malignant neoplasms in males, and 0.7% of all breast cancers. The mean patient age in this study was $59.8{\pm}9.5$ (39-74) years. The mean time between first symptom and diagnosis was $32.4{\pm}5.3$ (3-60) months. Histology revealed infiltrative ductal carcinoma in 81.3% of patients. The most common detected molecular subtype was luminal A, in 12 (75%) patients. Estrogen receptor rate (93.8%) in male breast cancer patients was significantly higher than that in female breast cancer (70.8% in all females, p = 0.003; 68.2% in postmenopausal females, p = 0.002) patients. Most of the tumors (56.3%) were grade 2. Tumor stage was T4 in 50% of males. The majority (56.3%) of the patients were stage III at diagnosis. Surgery, chemotherapy, radiotherapy and endocrine-therapy were applied to 62.5%, 62.5%, 81.2% and 73.3%, respectively. Loco-regional failure did not occur in any of the cases. All recurrences were metastastic. The 5-year disease-free and overall survival rates in male breast cancer patients were 58% and 68%, respectively. Conclusions: Tumors found in male breast cancer patients were similar in size to tumors found in females, but they advanced to T4 stage more rapidly because of the lack of breast parenchymal tissues. The rate of estrogen receptor expression tended to be higher in male breast cancer patients than in female breast cancer patients. Metastasis is the most important problem in initially non-metastatic male breast cancer patients.

Keywords

References

  1. Adibelli ZH, Oztekin O, Postaci H, Uslu A (2009). The diagnostic accuracy of mammography and ultrasound in the evaluation of male breast disease: a new algorithm. Breast Care, 4, 255-9. https://doi.org/10.1159/000226284
  2. Adibelli ZH, Oztekin O, Gunhan-Bilgen I, et al (2010). Imaging characteristics of male breast disease. Breast J, 16, 510-8. https://doi.org/10.1111/j.1524-4741.2010.00951.x
  3. Arslan UY, Oksuzoglu B, Ozdemir N, et al (2012). Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol, 29, 554-60. https://doi.org/10.1007/s12032-011-9978-9
  4. Atahan L, Yildiz F, Selek U, Sari S, Gurkaynak M (2006). Postoperative radiotherapy in the treatment of male breast carcinoma: a single institute experience. J Natl Med Assoc, 98, 559-63.
  5. Bagley CS, Wesley MN, Young RC, Lippman ME (1987). Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol, 10, 55-60. https://doi.org/10.1097/00000421-198702000-00013
  6. Chakravarthy A, Kim CR (2002). Post-mastectomy radiation in male breast cancer. Radiother Oncol, 65, 99-103. https://doi.org/10.1016/S0167-8140(02)00210-4
  7. Clarke M, Collins R, Darby S, et al (2005). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 366, 2087-106. https://doi.org/10.1016/S0140-6736(05)67887-7
  8. Cutuli B (2007). Strategies in treating male breast cancer. Expert Opin Pharmacother, 8, 193-202. https://doi.org/10.1517/14656566.8.2.193
  9. Cutuli B, Le-Nir CC, Serin D, et al (2010). Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol, 73, 246-54. https://doi.org/10.1016/j.critrevonc.2009.04.002
  10. Dabakuyo TS, Dialla O, Gentil J, et al (2012). Breast cancer in men in Cote d'Or (France): epidemiological characteristics, treatments and prognostic factors. Eur J Cancer Care (Engl), 21, 809-16. https://doi.org/10.1111/j.1365-2354.2012.01365.x
  11. Engin K, Unsal M (1993). Cancer of the male breast: the Turkish experience. J Surg Oncol, 53, 128-32. https://doi.org/10.1002/jso.2930530216
  12. Erkin O, Ardahan M (2014). Breast cancer and breast selfexamination in stamps history. Lokman Hekim Journal, 4, 22-8.
  13. Fentiman IS, Fourquet A, Hortobagyi GN (2006). Male breast cancer. Lancet, 367, 595-604. https://doi.org/10.1016/S0140-6736(06)68226-3
  14. Fentiman IS (2009). Male breast cancer: a review. Ecancermedicalscience, 3, 140.
  15. Fogh S, Hirsch AE, Langmead JP, et al (2011). Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. Clin Breast Cancer, 11, 39-45. https://doi.org/10.3816/CBC.2011.n.007
  16. Gennari R, Curigliano G, Jereczek-Fossa BA, et al (2004). Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J Oncol, 24, 663-70.
  17. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7. https://doi.org/10.1002/cncr.20312
  18. Giordano SH (2005). A review of the diagnosis and management of male breast cancer. Oncologist, 10, 471-9. https://doi.org/10.1634/theoncologist.10-7-471
  19. Gomez-Raposo C, Zambrana Tevar F, Sereno Moyano M, Lopez Gomez M, Casado E (2010). Male breast cancer. Cancer Treat Rev, 36, 451-7. https://doi.org/10.1016/j.ctrv.2010.02.002
  20. Goss PE, Reid C, Pintilie M, Lim R, Miller N (1999). Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer, 85, 629-39. https://doi.org/10.1002/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V
  21. Gradishar WJ, Anderson BO, Balassanian R, et al (2015). Breast cancer version 2.2015. J Natl Compr Canc Netw, 13, 448-75.
  22. Gunhan-Bilgen I, Bozkaya H, Ustun E, Memis A (2002). Male breast disease: clinical, mammographic, and ultrasonographic features. Eur J Radiol, 43, 246-55. https://doi.org/10.1016/S0720-048X(01)00483-1
  23. Hayashi H, Kimura M, Yoshimoto N, et al (2009). A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Breast Cancer, 16, 136-40. https://doi.org/10.1007/s12282-008-0060-1
  24. Haydaroglu A, Dubova S, Ozsaran Z, et al (2005). Breast cancer in Ege University “evaluation of 3897 cases”. J Breast Health, 1, 6-11.
  25. Hayes TG (2009). Pharmacologic treatment of male breast cancer. Expert Opin Pharmacother, 10, 2499-510. https://doi.org/10.1517/14656560903200634
  26. Nordman IC, Dalley DN (2008). Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment? Breast J, 14, 562-9. https://doi.org/10.1111/j.1524-4741.2008.00648.x
  27. Ozmen V (2014). Breast cancer in Turkey: clinical and histopathological characteristics (Analysis of 13.240 Patients). J Breast Health, 10, 98-105. https://doi.org/10.5152/tjbh.2014.1988
  28. Patten DK, Sharifi LK, Fazel M (2013). New approaches in the management of male breast cancer. Clin Breast Cancer, 13, 309-14. https://doi.org/10.1016/j.clbc.2013.04.003
  29. Reis LO, Dias FG, Castro MA, Ferreira U (2011). Male breast cancer. Aging Male, 14, 99-109. https://doi.org/10.3109/13685538.2010.535048
  30. Ribeiro GG, Swindell R, Harris M, Banerjee SS, Cramer A (1996). A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. The Breast, 5, 141-6. https://doi.org/10.1016/S0960-9776(96)90058-2
  31. Selcukbiricik F, Tural D, Aydogan F, et al (2013). Male breast cancer: 37-year data study at a single experience center in Turkey. J Breast Cancer, 16, 60-5. https://doi.org/10.4048/jbc.2013.16.1.60
  32. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  33. Sipetic-Grujicic SB, Murtezani ZH, Neskovic-Konstatinovic ZB, et al (2014). Multivariate analysis of prognostic factors in male breast cancer in Serbia. Asian Pac J Cancer Prev, 15, 3233-8. https://doi.org/10.7314/APJCP.2014.15.7.3233
  34. Somerville P (1952). Carcinoma of the male breast; a report of 19 cases and a review of the literature. Br J Surg, 39, 296-303. https://doi.org/10.1002/bjs.18003915603
  35. Yildirim E, Berberoglu U (1998). Male breast cancer: a 22-year experience. Eur J Surg Oncol, 24, 548-52. https://doi.org/10.1016/S0748-7983(98)93608-3
  36. Zygogianni AG, Kyrgias G, Gennatas C, et al (2012). Male breast carcinoma: epidemiology, risk factors and current therapeutic approaches. Asian Pac J Cancer Prev, 13, 15-9. https://doi.org/10.7314/APJCP.2012.13.1.015

Cited by

  1. A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study vol.144, pp.2, 2018, https://doi.org/10.1007/s00432-017-2554-8